Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cerebroside sulfatase - Takeda

Drug Profile

Cerebroside sulfatase - Takeda

Alternative Names: Arylsulfatase A; HGT-1110; HGT-1111; Metazym; Recombinant human arylsulfatase A; Recombinant human cerebroside sulfatase; Recombinant human sulfatidate sulfatase; rhASA; SHP-611; Sulfatide sulfatase; TAK 611

Latest Information Update: 02 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymenex A/S
  • Developer Assistance Publique Hopitaux de Paris; Takeda; Zymenex A/S
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action Cerebroside sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Metachromatic leukodystrophy

Most Recent Events

  • 30 Apr 2019 Phase-II clinical trials in Metachromatic leukodystrophy (In children) in Spain, Netherlands, Mexico, Israel, Canada, Brazil, Belgium, USA, France, Germany (Intrathecal) (NCT03771898)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 11 Dec 2018 Shire plans a phase II trial for Metachromatic Leukodystrophy in USA, Brazil, Belgium, Canada, Denmark, France, Germany, Israel, Japan, Mexico, Netherlands, Spain and the UK , (NCT03771898)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top